NDUFB8
ENSG00000166136
Target class
Enzyme
Chromosome
10
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- NDUFB8
- Gene name
- NADH:ubiquinone oxidoreductase subunit B8
- Gene symbol
- NDUFB8
- Protein name
- NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial (Complex I-ASHI) (CI-ASHI) (NADH-ubiquinone oxidoreductase ASHI subunit)
- ASHI
- CI-ASHI
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase supernumerary subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 305.03
- Tissue specificity (Gini)
- 0.172
- Tissue specificity (tau)
- 0.484
- KEGG gene identifiers
- hsa:4714
- Protein interaction confidence
- 0.91713
- Protein interaction partners
- 131
- R-HSA-1268020
- R-HSA-611105
- R-HSA-6799198
- End position
- 100530000
- Start position
- 100523668
- Chromosome
- 10
- Strand
- Reverse
- Mitochondrion inner membrane
- Single-pass membrane protein
- Matrix side .
- Mitochondria
Publication evidence
- PubMed 12611891
- Tissue specificity (tau)
- 0.483813
- Expression inequality (Gini)
- 0.172416
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)
- 305.03
- Brain - Anterior cingulate cortex (BA24)
- 273.1
- Brain - Cerebellar Hemisphere
- 248.23
- Brain - Cortex
- 247.47
- Brain - Cerebellum
- 220.8
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)305.03
- Brain - Anterior cingulate cortex (BA24)273.1
- Brain - Cerebellar Hemisphere248.23
- Brain - Cortex247.47
- Brain - Cerebellum220.8
- Brain - Hypothalamus220.3
- Colon - Sigmoid214.18
- Esophagus - Gastroesophageal Junction212.1
- Brain - Amygdala210.18
- Esophagus - Muscularis202.7
- Cells - EBV-transformed lymphocytes202.16
- Artery - Tibial194.56
- Artery - Aorta191.45
- Brain - Hippocampus188.46
- Brain - Caudate (basal ganglia)183.91
- Brain - Nucleus accumbens (basal ganglia)182.24
- Pituitary180.94
- Brain - Substantia nigra178.16
- Brain - Putamen (basal ganglia)177.01
- Heart - Atrial Appendage174.32
- Artery - Coronary171.55
- Fallopian Tube167.17
- Kidney - Medulla166.96
- Uterus166.71
- Heart - Left Ventricle162.66
And 29 more, listed on the interactive page.
- GO:0005739
- GO:0005743
- GO:0005759
- GO:0045271
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor